Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus teriflunomide in relapsing multiple sclerosis
2015-005418-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate. Started Jul 2016; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-005418-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005418-31.